Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include Occupational and environmental lung diseases, Fibroblast Growth Factor Research, Metal complexes synthesis and properties, and Cancer Research and Treatments.
A recurrent missense variant in the PPIB gene encoding peptidylprolyl isomerase B underlies adult-onset autosomal dominant optic atrophy
Improved Systemic Immunochemotherapy Employing an Oxaliplatin-TLR7/8 Agonist Prodrug Strategy.
<i>MGMT</i> Promoter and Enhancer Methylation in Melanoma Brain Metastases and Glioblastoma: Shared and Distinct Features.
Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma.
Naphthoquinone-derived tridentate Ru(II) and Os(II) organometallics with exceptional cytotoxicity: synthesis, characterization, stability in aqueous solution and biological <i>in vitro</i> evaluation.
Structure-Activity Relationships of Silver(I)- and Gold(I)-NHC Complexes Reveal Distinctly Different Responses of Cisplatin-Resistant Ovarian Cancer to Bis-NHC-Gold(I) Derivatives.
Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.
ABCG2-mediated SN-38 efflux drives resistance to Sacituzumab govitecan in urothelial carcinoma
Effective targeting of PDGFRA-altered high-grade glioma with avapritinib
Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors
Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.
Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors.
Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonists.
A new fluorescent oxaliplatin(iv) complex with EGFR-inhibiting properties for the treatment of drug-resistant cancer cells.
Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma.
Exploring the Structure-Activity Relationships of Albumin-Targeted Picoplatin-Based Platinum(IV) Prodrugs.
Selectivity for TP53 signalling drives the mode of action of a highly potent <i>N</i>,<i>O</i>,<i>O</i>-tridentate naphthoquinone-based organo-ruthenium anticancer drug candidate.
Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma
Dual-Mode Wheat Germ Agglutinin Labeling - A Versatile Cell Segmentation Strategy for High-Resolution LA-ICP-TOFMS Bioimaging.
LA-ICP-TOFMS Imaging Reveals Significant Influence of Cancer Cell Resistance on Oxaliplatin Compartmentalization in the Tumor Microenvironment.
Structural variations in the <i>trans</i>-carboxylate/chlorido axis that impact the mode of action of Pt(ii) complexes.
Exploring the Anticancer Properties of 4-Phenylthiazole-Based Ru(II) and Os(II) Metallacycles Featuring 1-Methylimidazole as <i>N</i>-Donor Functionality.
Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens
Stepwise optimization of tumor-targeted dual-action platinum(iv)-gemcitabine prodrugs.
The tyrosine kinase inhibitor Nintedanib induces lysosomal dysfunctionality: Role of protonation-dependent crystallization processes
EPEN-12. EZHIP IMPACTS CELLULAR DIFFERENTIATION IN POSTERIOR FOSSA GROUP A EPENDYMOMA
Anthocyanin-Rich Berry Extracts Affect SN-38-Induced Response: A Comparison of Non-Tumorigenic HCEC-1CT and HCT116 Colon Carcinoma Cells.
Characterization of a Syngeneic Orthotopic Model of Cholangiocarcinoma by [<sup>18</sup>F]FDG-PET/MRI.
Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models
Precision Oncology Approach for Urachal Carcinoma: A Clinical Case Report.